A US Food and Drug Administration (FDA) inspection can go well for days and still come apart at the very end. That’s the pattern one expert has seen play out repeatedly, and why he considers the closeout meeting the single riskiest moment of an inspection.
“The morning the inspection closes out is the most critical time,” QualityHub Principal Consultant Dan McMinn said.
Issues Can Resurface Without Warning
During daily opening and closing meetings or after any discussion of a challenging issue, the company’s inspection host or lead should ask directly whether concerns remain, and work aggressively to resolve anything that comes up before it hardens into a formal inspectional finding, McMinn said.
But even careful preparation doesn’t guarantee a clean close.
“I’ve seen situations where everything looks fine, and then suddenly an issue you discussed with the investigator two days earlier – perhaps one you thought was resolved – turns into a finding,” McMinn said.
“Friday is the ‘hold your breath’ day, because that’s when the investigator could say, ‘We think there are some issues here, so we’re going to come back next week.’” – Dan McMinn
He isn’t entirely sure why that happens, whether it’s a company letting its guard down as the inspection winds toward its end, or something more deliberate on the investigator’s side.
“Sometimes you can tell that the investigator is reading the room to decide if they want to give a finding or not,” McMinn said. “It’s a tricky time to manage, and keeping the same consistent professionalism all the way to the end is difficult. But if you can do that, it absolutely helps.”
Why Fridays Carry Extra Risk
Consultant McMinn said a Friday closeout carries added risk because of the scheduling pressure investigators are under. Inspections typically begin on a Monday, and absent major issues, investigators try to wrap up within the week – often aiming to leave by midday Friday, particularly if they’re traveling.
“Friday is the ‘hold your breath’ day, because that’s when the investigator could say, ‘We think there are some issues here, so we’re going to come back next week,’” he said.
The discipline that prevents that outcome has to run through the whole inspection, not just the final morning, McMinn said. Rather than waiting for an unresolved issue to resurface on its own, he recommends proactively bringing new information back into the conversation as soon as it becomes available.
“If there’s an issue that hasn’t been resolved to your satisfaction, and new information comes in, you actively bring it back into the discussion so it can be resolved and closed out before the last day,” McMinn said.
He noted that an issue raised early in the week and left unresolved until Friday morning is being addressed too late, as the moment for proactively working it through has already passed.
Who Should Be in the Room
McMinn said the closeout meeting should generally include the same core group present at the opening. (Related Story: “First Impressions, Zero Second Chances: Mastering the FDA Opening Meeting,” QualityHub, Sept. 14, 2026.)
That includes the person with executive or management responsibility, the inspection host or lead, and the scribe. Subject Matter Experts (SMEs) remain available to be called in as needed. (Related Story: “Before FDA Arrives, Get Your Response Team Right, Part 1: The Host, the Rules, the Request Manager,” QualityHub, Sept. 2, 2026.)
But he said the right group size can shift depending on how the inspection has gone. In more contentious situations, a smaller room can serve the company better than a large one.
“If it was a contentious inspection, you may want to have a more direct conversation for management to be able to put together a more forceful response, rather than diluting it with a bunch of people in the room,” McMinn said.
The Witness Rule
The closing meeting is still part of the inspection; it isn’t over until the investigator leaves the site. McMinn says one safeguard he never skips is never leaving a company representative alone with an FDA investigator, even briefly.
“You always want to have a witness in the room with you,” he said. “If you have your inspection host or lead, your request manager, and your scribe in the room, only one of you should step out at a time unless someone’s there to backfill.” (Related Story: “Before FDA Arrives, Get Your Response Team Right, Part 2: Scribes, Escorts, and SMEs Round Out the Team,” QualityHub, Sept. 2, 2026.)
The concern, he said, is avoiding any dispute over what was said in a private exchange – a “while I was away, your scribe told me this was a problem” situation that’s far harder to manage after the fact.
McMinn further noted that companies vary in how openly they share scribe notes internally during a closeout, particularly when the inspection is going poorly or if confidential information is being discussed.
“It depends on the culture of the company, and how challenging the inspection is,” he said.
